Celldex drops eczema program after Phase 2 trial misses endpoints

Celldex Therapeutics is discontinuing development of barzolvolimab for moderate-to-severe atopic dermatitis (eczema) after its Phase 2 study failed to meet the primary itch endpoint or key secondary measures.

The study enrolled 131 patients. At Week 16, itch scores fell 29.2% with the 300 mg dose and 16.2% with the 150 mg dose, compared with 19.5% on placebo; neither dose showed a statistically significant advantage over placebo.

Measures of eczema severity and skin clearance also did not meaningfully separate from placebo, and extending treatment to Week 32 did not produce added improvement.

Celldex said the results fell short of its internal threshold for continued development. The drug was well tolerated, and the company said the data suggest mast cells may contribute to eczema but are not a primary driver.

The setback is specific to eczema; Celldex continues to develop barzolvolimab for chronic hives and other indications.

Sources:

Celldex Reports Results from Phase 2 Study ...

Celldex ends eczema drug development after mid-stage trial failure

Celldex Reports Third Quarter Financial Results and ...

Celldex drug stumbles in eczema; Epigenetic editing startup cuts staff

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Atopic Dermatitis

Celldex ends eczema drug development after mid-stage trial failure

Celldex Ends Program for its Atopic Dermatitis Treatment After Phase 2 Miss Points to Limited Role for Mast Cells | BioPharm International

Celldex Therapeutics, Inc.

Celldex halts eczema drug development after trial failure; shares fall more than 3%

99.1

Celldex culls eczema study after Phase 2 failure

Celldex Scraps Eczema Drug After Phase 2 Miss, Turning Focus to 2027 Hives Filing

Celldex Drops Atopic Dermatitis Study Following Weak Phase 2 Pruritus Data - Celldex Therapeutics (NASDAQ

Celldex discontinues atopic dermatitis program after trial miss

Celldex reports barzolvolimab trial misses primary endpoint